Stem-cell-derived beta cells mature metabolically upon murine engraftment.

AIMS/HYPOTHESIS: The use of stem-cell-derived islets (SC-islets) as a source for cell-based therapy of type 1 diabetes shows great potential. However, SC-islets have a metabolically immature phenotype compared with primary human islets, the current 'gold standard' cell therapy. SC-islet metabolic immaturity is most evident in their aberrant reactivity to pyruvate, which could be associated with clinically significant dysregulation of insulin secretion. We thus aimed to study whether this immature metabolic phenotype persists upon engraftment in mice.

METHODS

This study was conducted by differentiating the H1 human embryonic stem-cell line into pancreatic islets (SC-islets) using a well-established seven-stage differentiation protocol. SC-islets were implanted under the kidney capsule of immunocompromised NOD-scid-gamma mice for 1-4 months. Metabolic and morphological assays of SC-islets pre- and post-implantation were performed (in parallel to cadaveric donor islets) using LC-MS metabolomics, electron microscopy, immunohistochemistry analyses and dynamic insulin secretion assays.

RESULTS

SC-islets had the capability of dynamically controlling mouse blood glucose levels by 3 months post-implantation. Murine engraftment led to maturation of various metabolic aspects of SC-islets, leading them to resemble human donor islets more closely. Mitochondrial number increased from a mean of 0.38 mitochondria/µm in vitro to 0.67 mitochondria/µm following 4 months of engraftment (p=0.0004). Conversely, changes in mitochondrial morphology were cell-specific and correlated more with the insulin granule crystallisation status of a given beta cell than the timepoint of the SC-islet sample. Glucose-sensitive tricarboxylic acid cycle activity increased, with the enrichment of labelled carbons into citrate in high glucose increasing from 12% in vitro to 28.7% 4 months post-engraftment (p<0.0001). Additionally, glucose-sensitive insulin secretion increased at the same time as pyruvate-reactive insulin secretion decreased, with the pyruvate-to-glucose reactivity ratio decreasing from 2.1 in vitro to 0.5 at 4 months post-engraftment (p=0.013). Lowered pyruvate reactivity was accompanied by the downregulation of the pyruvate/lactate transporter monocarboxylate transporter 1 (MCT1).

CONCLUSIONS/INTERPRETATION: An in vivo environment is beneficial for the metabolic maturation of SC-islets, leading them to more closely resemble human donor islets. We show that the aberrant metabolite trafficking pathways seen in SC-islets are robustly diminished following engraftment. Our results suggest that metabolic dysregulation is not a major safety concern for clinical SC-islet implantation after prolonged periods of engraftment.